Document is current
Any future updates will be listed below
-
Authors
Koyama, Satoshi https://orcid.org/0000-0002-9286-0360
Yu, Zhi https://orcid.org/0000-0003-4810-3474
Choi, Seung Hoan
Jurgens, Sean J. https://orcid.org/0000-0002-1605-9782
Selvaraj, Margaret Sunitha
Klarin, Derek https://orcid.org/0000-0002-4636-5780
Huffman, Jennifer E. https://orcid.org/0000-0002-9672-2491
Clarke, Shoa L. https://orcid.org/0000-0002-6592-1172
Zhang, Selena K. https://orcid.org/0000-0003-4499-4820
Trinh, Michael N.
Ravi, Akshaya
Dron, Jacqueline S. https://orcid.org/0000-0002-3045-6530
Spinks, Catherine
Surakka, Ida
Bhatnagar, Aarushi https://orcid.org/0009-0004-4699-6779
Lannery, Kim
Hornsby, Whitney
Damrauer, Scott M. https://orcid.org/0000-0001-8009-1632
Chang, Kyong-Mi https://orcid.org/0000-0001-6811-9364
Lynch, Julie A. https://orcid.org/0000-0003-0108-2127
Assimes, Themistocles L. https://orcid.org/0000-0003-2349-0009
Tsao, Philip S. https://orcid.org/0000-0001-7274-9318
Rader, Daniel J. https://orcid.org/0000-0002-9245-9876
Cho, Kelly
Peloso, Gina M. https://orcid.org/0000-0002-5355-8636
Ellinor, Patrick T. https://orcid.org/0000-0002-2067-0533
Sun, Yan V. https://orcid.org/0000-0002-2838-1824
Wilson, Peter W. F. https://orcid.org/0000-0002-5653-7056
,
Natarajan, Pradeep https://orcid.org/0000-0001-8402-7435
- License Information
-
More Information
Article History
Received: 17 September 2024
Accepted: 27 April 2026
First Online: 25 May 2026
Competing interests
: D.K. is a scientific advisor and reports consulting fees from Bitterroot Bio unrelated to the present work. P.T.E. receives sponsored research support from Bayer AG, Bristol Myers Squibb, Pfizer and Novo Nordisk; he has also served on advisory boards or consulted for Bayer AG. P.N. reports research grants from Allelica, Amgen, Apple, Boston Scientific, Cleerly, Genentech/Roche, Ionis, Novartis and Silence Therapeutics; personal fees from AIRNA, Allelica, Apple, AstraZeneca, Bain Capital, Blackstone Life Sciences, Bristol Myers Squibb, Creative Education Concepts, CRISPR Therapeutics, Eli Lilly, Esperion Therapeutics, Foresite Capital, Foresite Labs, Genentech/Roche, GV, HeartFlow, Incyte, Magnet Biomedicine, Merck, Novartis, Novo Nordisk, TenSixteen Bio and Tourmaline Bio; equity in Bolt, Candela, Mercury, MyOme, Parameter Health, Preciseli and TenSixteen Bio; royalties from Recora for intensive cardiac rehabilitation; and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work. The remaining authors declare no competing interests.
